4-88007742-C-T
Position:
Variant summary
Our verdict is Benign. Variant got -14 ACMG points: 0P and 14B. BP4_StrongBP6BP7BS1BS2
The NM_000297.4(PKD2):c.9C>T(p.Asn3Asn) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000119 in 1,207,562 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00011 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00012 ( 1 hom. )
Consequence
PKD2
NM_000297.4 synonymous
NM_000297.4 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: 0.386
Genes affected
PKD2 (HGNC:9009): (polycystin 2, transient receptor potential cation channel) This gene encodes a member of the polycystin protein family. The encoded protein is a multi-pass membrane protein that functions as a calcium permeable cation channel, and is involved in calcium transport and calcium signaling in renal epithelial cells. This protein interacts with polycystin 1, and they may be partners in a common signaling cascade involved in tubular morphogenesis. Mutations in this gene are associated with autosomal dominant polycystic kidney disease type 2. [provided by RefSeq, Mar 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -14 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.74).
BP6
Variant 4-88007742-C-T is Benign according to our data. Variant chr4-88007742-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 903899.We mark this variant Likely_benign, oryginal submissions are: {Uncertain_significance=1, Likely_benign=1}.
BP7
Synonymous conserved (PhyloP=0.386 with no splicing effect.
BS1
Variant frequency is greater than expected in population mid. gnomad4_exome allele frequency = 0.00012 (127/1058142) while in subpopulation MID AF= 0.00198 (6/3030). AF 95% confidence interval is 0.000862. There are 1 homozygotes in gnomad4_exome. There are 62 alleles in male gnomad4_exome subpopulation. Median coverage is 28. This position pass quality control queck.
BS2
High AC in GnomAd4 at 17 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PKD2 | NM_000297.4 | c.9C>T | p.Asn3Asn | synonymous_variant | 1/15 | ENST00000237596.7 | NP_000288.1 | |
PKD2 | XM_011532028.3 | c.9C>T | p.Asn3Asn | synonymous_variant | 1/14 | XP_011530330.1 | ||
PKD2 | NR_156488.2 | n.108C>T | non_coding_transcript_exon_variant | 1/14 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000114 AC: 17AN: 149420Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
17
AN:
149420
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000207 AC: 12AN: 57896Hom.: 0 AF XY: 0.000202 AC XY: 7AN XY: 34576
GnomAD3 exomes
AF:
AC:
12
AN:
57896
Hom.:
AF XY:
AC XY:
7
AN XY:
34576
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000120 AC: 127AN: 1058142Hom.: 1 Cov.: 28 AF XY: 0.000120 AC XY: 62AN XY: 515084
GnomAD4 exome
AF:
AC:
127
AN:
1058142
Hom.:
Cov.:
28
AF XY:
AC XY:
62
AN XY:
515084
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000114 AC: 17AN: 149420Hom.: 0 Cov.: 32 AF XY: 0.0000960 AC XY: 7AN XY: 72884
GnomAD4 genome
AF:
AC:
17
AN:
149420
Hom.:
Cov.:
32
AF XY:
AC XY:
7
AN XY:
72884
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:2
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Polycystic kidney disease 2 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jan 13, 2018 | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. - |
not provided Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The PKD2 p.Asn3Asn variant was not identified in the literature nor was it identified in the ClinVar, LOVD 3.0, ADPKD Mutation Database or PKD1-LOVD databases. The variant was identified in dbSNP (ID: rs773343245) and in control databases in 14 of 85778 chromosomes at a frequency of 0.000163 (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: Other in 2 of 2566 chromosomes (freq: 0.000779), Ashkenazi Jewish in 4 of 5596 chromosomes (freq: 0.000715), European (non-Finnish) in 6 of 36322 chromosomes (freq: 0.000165) and South Asian in 2 of 14048 chromosomes (freq: 0.000142), while the variant was not observed in the African, Latino, East Asian, and European (Finnish) populations. The p.Asn3Asn variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. Two of four in silico or computational prediction software programs (SpliceSiteFinder and MaxEntScan) predict the creation of a new 5' splice site, however this is not very predictive of pathogenecity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. - |
Autosomal dominant polycystic kidney disease Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 22, 2023 | - - |
PKD2-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 04, 2019 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at